Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase
Kenneth R. Hallows, … , Lee A. Witters, J. Kevin Foskett
Kenneth R. Hallows, … , Lee A. Witters, J. Kevin Foskett
Published June 15, 2000
Citation Information: J Clin Invest. 2000;105(12):1711-1721. https://doi.org/10.1172/JCI9622.
View: Text | PDF
Article

Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase

  • Text
  • PDF
Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is an ATP-gated Cl– channel that regulates other epithelial transport proteins by uncharacterized mechanisms. We employed a yeast two-hybrid screen using the COOH-terminal 70 residues of CFTR to identify proteins that might be involved in such interactions. The α1 (catalytic) subunit of AMP-activated protein kinase (AMPK) was identified as a dominant and novel interacting protein. The interaction is mediated by residues 1420–1457 in CFTR and by the COOH-terminal regulatory domain of α1-AMPK. Mutations of two protein trafficking motifs within the 38–amino acid region in CFTR each disrupted the interaction. GST-fusion protein pull-down assays in vitro and in transfected cells confirmed the CFTR-α1-AMPK interaction and also identified α2-AMPK as an interactor with CFTR. AMPK is coexpressed in CFTR-expressing cell lines and shares an apical distribution with CFTR in rat nasal epithelium. AMPK phosphorylated full-length CFTR in vitro, and AMPK coexpression with CFTR in Xenopus oocytes inhibited cAMP-activated CFTR whole-cell Cl– conductance by approximately 35–50%. Because AMPK is a metabolic sensor in cells and responds to changes in cellular ATP, regulation of CFTR by AMPK may be important in inhibiting CFTR under conditions of metabolic stress, thereby linking transepithelial transport to cell metabolic state.

Authors

Kenneth R. Hallows, Viswanathan Raghuram, Bruce E. Kemp, Lee A. Witters, J. Kevin Foskett

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
In vitro phosphorylation of CFTR by AMPK. CFTR was immunoprecipitated fr...
In vitro phosphorylation of CFTR by AMPK. CFTR was immunoprecipitated from CHO-BQ2 cell lysates (lanes 2–5) before phosphorylation, SDS-PAGE, and autoradiography. In lane 2, no exogenous kinase was added to the phosphorylation buffer. In lanes 3 and 4, affinity-purified AMPK holoenzyme was added to immunoprecipitated CFTR in the absence or presence of 0.2 mM AMP, respectively. Affinity-purified α1-1-312 was added to immunoprecipitate in lane 5. As a negative control, AMPK holoenzyme was added to an immunoprecipitate from CHO cells that do not express CFTR (lane 1). Results shown are representative of three replicate experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts